An effective dendritic cell‐based vaccine containing glioma stem‐like cell lysate and CpG adjuvant for an orthotopic mouse model of glioma

Owing to the limited therapeutic efficacy of glioma vaccines, new strategies are required to improve cancer vaccines. Our study aimed to assess the therapeutic efficacy of a glioma vaccine called STDENVANT. This vaccine, comprising glioma stem‐like cell (GSC) lysate, dendritic cells (DCs), and Toll‐like receptor (TLR) 9 agonist CpG motif‐containing oligodeoxynucleotides (CpG ODNs), was assessed using a GL261‐C57BL/6 orthotopic mouse model of glioma. STDENVANT markedly improved survival and tumor regression by enhancing anti‐tumor immune function. Moreover, STDENVANT upregulated programmed death 1 (PD‐1) and its ligand PD‐L1 on effector T cells, DCs, and glioma tissues, resulting in the accumulation of regulatory T (Treg) cells in the brain and lymph nodes. Combinatorial administration of anti‐PD‐L1 antibody and STDENVANT conferred a greater survival advantage and decreased the Treg cell population in the brain. The present results indicate that PD‐L1 blockade can promote tumor regression via STDENVANT in a mouse model of glioma, and combinatorial administration of anti‐PD‐L1 antibody and STDENVANT increases the therapeutic anti‐tumor efficacy of treatment.

• Publication year

  2019

• Venue

  International Journal of Cancer

• Publication date

  2019-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/ijc.32008PMID 30565657
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Increased PD‐L1 expression in breast and colon cancer stem cells

  2017cited by this paper
• Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy

  2017cited by this paper
• Surface PD-L1, E-cadherin, CD24, and VEGFR2 as markers of epithelial cancer stem cells associated with rapid tumorigenesis

  2017cited by this paper
• Aspergillus fumigatus Cell Wall &agr;-(1,3)-Glucan Stimulates Regulatory T-Cell Polarization by Inducing PD-L1 Expression on Human Dendritic Cells

  2017cited by this paper
• Targeting CpG Adjuvant to Lymph Node via Dextran Conjugate Enhances Antitumor Immunotherapy.

  2017cited by this paper
• PD‐L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation

  2017cited by this paper
• Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape.

  2017cited by this paper
• Cancer stem cells revisited

  2017cited by this paper
• PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome

  2017cited by this paper
• Vaccine-based immunotherapeutic approaches to gliomas and beyond

  2017cited by this paper
• PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells

  2017cited by this paper
• Vaccines for established cancer: overcoming the challenges posed by immune evasion

  2016cited by this paper
• CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells.

  2016cited by this paper
• Antigen-specific T cell response from dendritic cell vaccination using side population cell-associated antigens targets hepatocellular carcinoma

  2016cited by this paper
• Targeting breast cancer stem cells by dendritic cell vaccination in humanized mice with breast tumor: preliminary results

  2016cited by this paper
• PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

  2016cited by this paper
• PD-L1 Expression Is Associated with Tumor FOXP3+ Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient

  2016cited by this paper
• Structural and functional features of central nervous system lymphatics

  2015cited by this paper
• Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites

  2015cited by this paper
• Metastatic spread in patients with non-small cell lung cancer is associated with a reduced density of tumor-infiltrating T cells

  2015cited by this paper
• Defining dendritic cells.

  2015cited by this paper
• Immune modulating effects of cyclophosphamide and treatment with tumor lysate/CpG synergize to eliminate murine neuroblastoma

  2015cited by this paper
• Immune responses to human cancer stem‐like cells/cancer‐initiating cells

  2015cited by this paper
• Immunotherapy with dendritic cells loaded with glioblastoma stem cells: from preclinical to clinical studies

  2015cited by this paper
• LPS-conditioned dendritic cells confer endotoxin tolerance contingent on tryptophan catabolism.

  2015cited by this paper
• Hsp90 regulates autophagy and plays a role in cancer therapy

  2015cited by this paper
• Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer.

  2014cited by this paper
• Mouse glioma immunotherapy mediated by A2B5+ GL261 cell lysate-pulsed dendritic cells

  2014cited by this paper
• Clinical use of dendritic cells for cancer therapy.

  2014cited by this paper
• Glioma Stem Cells and Immunotherapy for the Treatment of Malignant Gliomas

  2013cited by this paper
• PD-L1 signal on liver dendritic cells is critical for Foxp3(+)CD4(+)CD25(+) Treg and liver tolerance induction in mice.

  2013cited by this paper
• What Are the Molecules Involved in Regulatory T-Cells Induction by Dendritic Cells in Cancer?

  2013cited by this paper
• Monocyte‐derived dendritic cells from breast cancer patients are biased to induce CD4+CD25+Foxp3+ regulatory T cells

  2012cited by this paper
• CD8α+ and CD8α− DC subsets from BCG‐infected mice inhibit allergic Th2‐cell responses by enhancing Th1‐cell and Treg‐cell activity respectively

  2012cited by this paper
• Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

  2010cited by this paper
• Prognostic significance and mechanism of Treg infiltration in human brain tumors.

  2010cited by this paper
• Differential induction of inflammatory cytokines by dendritic cells treated with novel TLR-agonist and cytokine based cocktails: targeting dendritic cells in autoimmunity

  2010cited by this paper
• A2B5 Cells from Human Glioblastoma have Cancer Stem Cell Properties

  2010cited by this paper
• Antigen‐Specific T‐Cell Response from Dendritic Cell Vaccination Using Cancer Stem‐Like Cell‐Associated Antigens

  2009cited by this paper
• CD133 as a Marker for Cancer Stem Cells: Progresses and Concerns

  2009cited by this paper
• Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists.

  2009cited by this paper
• Induction of Treg by monocyte‐derived DC modulated by vitamin D3 or dexamethasone: Differential role for PD‐L1

  2009cited by this paper
• CpG oligonucleotides for immunotherapeutic treatment of neuroblastoma.

  2009cited by this paper
• Toll‐like receptor ligand activation of murine bone marrow‐derived dendritic cells

  2009cited by this paper
• Inhibitory B7-family molecules in the tumour microenvironment

  2008cited by this paper
• In Vivo Vaccination With Tumor Cell Lysate Plus CpG Oligodeoxynucleotides Eradicates Murine Glioblastoma

  2007cited by this paper
• Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas.

  2006cited by this paper
• PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression

  2006cited by this paper
• Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.

  2005cited by this paper
• Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial.

  2005cited by this paper
• Human Plasmacytoid Dendritic Cells Activated by CpG Oligodeoxynucleotides Induce the Generation of CD4+CD25+ Regulatory T Cells1

  2004cited by this paper
• CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies

  2003cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper

• Disrupting PDGFRA-driven immune evasion in glioma: vaccine-based strategies on the horizon

  2026cites this paper
• Immune Cell Interplay in the Fight Against GBM

  2025cites this paper
• Dendritic cells as orchestrators of anticancer immunity and immunotherapy

  2024cites this paper
• CHD1L accelated the progression of cutaneous squamous cell carcinoma via promoting PI3K/PD-L1 signaling pathway induced M2 polarization of TAMs

  2024cites this paper
• Identification and validation of potential prognostic biomarkers in glioblastoma via the mesenchymal stem cell infiltration level

  2024cites this paper
• Surgically Derived Cancer Cell Membrane-Coated R837-Loaded Poly(2-Oxazoline) Nanoparticles for Prostate Cancer Immunotherapy

  2023cites this paper
• Incorporation of a TGF-β2-inhibiting oligodeoxynucleotide molecular adjuvant into a tumor cell lysate vaccine to enhance antiglioma immunity in mice

  2023cites this paper
• Cancer stem cells in brain tumors: From origin to clinical implications

  2023cites this paper
• Efficacy of Whole Cancer Stem Cell-Based Vaccines: A Systematic Review of Preclinical and Clinical Studies.

  2022cites this paper
• A photodynamically sensitized dendritic cell vaccine that promotes the anti-tumor effects of anti-PD-L1 monoclonal antibody in a murine model of head and neck squamous cell carcinoma

  2022cites this paper
• Cry1Ac Protoxin Confers Antitumor Adjuvant Effect in a Triple-Negative Breast Cancer Mouse Model by Improving Tumor Immunity

  2022cites this paper
• A Smart Silk‐Based Microneedle for Cancer Stem Cell Synergistic Immunity/Hydrogen Therapy

  2022cites this paper
• Cry1Ac Protoxin Confers Antitumor Adjuvant Effect in a Triple-Negative Breast Cancer Mouse Model by Improving Tumor Immunity.

  2022cites this paper
• The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy

  2022cites this paper
• Cytokine chemokine network in tumor microenvironment: Impact on CSC properties and therapeutic applications.

  2022cites this paper
• Trial watch: Dendritic cell (DC)-based immunotherapy for cancer

  2022cites this paper
• TLR9 and Glioma: Friends or Foes?

  2022cites this paper
• Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End

  2021cites this paper
• Cryoimmunology: Opportunities and challenges in biomedical science and practice.

  2021cites this paper
• Downregulation of hsa_circ_0001836 Induces Pyroptosis Cell Death in Glioma Cells via Epigenetically Upregulating NLRP1

  2021cites this paper
• Selectively targeting cancer stem cells: Current and novel therapeutic strategies and approaches in the effective eradication of cancer

  2021cites this paper
• The Immune Privilege of Cancer Stem Cells: A Key to Understanding Tumor Immune Escape and Therapy Failure

  2021cites this paper
• Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma

  2021cites this paper
• Cell-Based Therapy for the Treatment of Glioblastoma: An Update from Preclinical to Clinical Studies

  2021cites this paper
• Adoptive Cell Therapy: A Novel and Potential Immunotherapy for Glioblastoma

  2020cites this paper
• Immunocompetent Mouse Models in the Search for Effective Immunotherapy in Glioblastoma

  2020cites this paper
• Clinical implication of cellular vaccine in glioma: current advances and future prospects

  2020cites this paper
• Comprehensively investigating the expression levels and the prognostic role of transforming growth factor beta-induced (TGFBI) in glioblastoma multiforme

  2020cites this paper
• Current state and future of co-inhibitory immune checkpoints for the treatment of glioblastoma

  2020cites this paper
• Recent Progress of Graphene Oxide as a Potential Vaccine Carrier and Adjuvant.

  2020cites this paper
• Immunotherapy: A Potential Approach to Targeting Cancer Stem Cells.

  2020cites this paper
• Expression levels of a gene signature in hiPSC associated with lung adenocarcinoma stem cells and its capability in eliciting specific antitumor immune‐response in a humanized mice model

  2020cites this paper
• TLR Agonist rHP-NAP as an Adjuvant of Dendritic Cell-Based Vaccine to Enhance Anti-Melanoma Response.

  2020cites this paper
• A Characterization of Dendritic Cells and Their Role in Immunotherapy in Glioblastoma: From Preclinical Studies to Clinical Trials

  2019cites this paper
• 3-Bromopyruvate inhibits the malignant phenotype of malignantly transformed macrophages and dendritic cells induced by glioma stem cells in the glioma microenvironment via miR-449a/MCT1.

  2019cites this paper
• Insights in the immunobiology of glioblastoma

  2019cites this paper
• Recent Advances in Cancer Stem Cell-Targeted Immunotherapy

  2019cites this paper